These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30956210)

  • 1. Riociguat for treatment of pulmonary hypertension in COPD: a translational study.
    Pichl A; Sommer N; Bednorz M; Seimetz M; Hadzic S; Kuhnert S; Kraut S; Roxlau ET; Kojonazarov B; Wilhelm J; Gredic M; Gall H; Tello K; Richter MJ; Pak O; Petrovic A; Hecker M; Schermuly RT; Grimminger F; Seeger W; Ghofrani HA; Weissmann N
    Eur Respir J; 2019 Jun; 53(6):. PubMed ID: 30956210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
    Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
    Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension.
    Ghofrani HA; Humbert M; Langleben D; Schermuly R; Stasch JP; Wilkins MR; Klinger JR
    Chest; 2017 Feb; 151(2):468-480. PubMed ID: 27263466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riociguat prevents hyperoxia-induced lung injury and pulmonary hypertension in neonatal rats without effects on long bone growth.
    Donda K; Zambrano R; Moon Y; Percival J; Vaidya R; Dapaah-Siakwan F; Luo S; Duncan MR; Bao Y; Wang L; Qin L; Benny M; Young K; Wu S
    PLoS One; 2018; 13(7):e0199927. PubMed ID: 29990355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Riociguat for the treatment of pulmonary hypertension.
    Hambly N; Granton J
    Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
    Koress C; Swan K; Kadowitz P
    Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cigarette Smoke-Induced Emphysema and Pulmonary Hypertension Can Be Prevented by Phosphodiesterase 4 and 5 Inhibition in Mice.
    Seimetz M; Parajuli N; Pichl A; Bednorz M; Ghofrani HA; Schermuly RT; Seeger W; Grimminger F; Weissmann N
    PLoS One; 2015; 10(6):e0129327. PubMed ID: 26058042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension.
    Benza R; Mathai S; Nathan SD
    Respir Med; 2017 Jan; 122 Suppl 1():S28-S34. PubMed ID: 27890470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
    Lian TY; Jiang X; Jing ZC
    Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Riociguat for the treatment of pulmonary hypertension: a safety evaluation.
    Binder C; Zotter-Tufaro C; Bonderman D
    Expert Opin Drug Saf; 2016 Dec; 15(12):1671-1677. PubMed ID: 27750459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Riociguat for the treatment of pulmonary hypertension.
    Schermuly RT; Janssen W; Weissmann N; Stasch JP; Grimminger F; Ghofrani HA
    Expert Opin Investig Drugs; 2011 Apr; 20(4):567-76. PubMed ID: 21391889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
    Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
    Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
    Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
    Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.
    Sandner P; Becker-Pelster EM; Stasch JP
    Nitric Oxide; 2018 Jul; 77():88-95. PubMed ID: 29738821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stimulation of soluble guanylate cyclase improves donor organ function in rat heart transplantation.
    Benke K; Németh BT; Sayour AA; Stark KA; Oláh A; Ruppert M; Szabó G; Korkmaz-Icöz S; Horváth EM; Benkő R; Hartyánszky I; Szabolcs Z; Merkely B; Radovits T
    Sci Rep; 2020 Mar; 10(1):5358. PubMed ID: 32210293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Riociguat: a novel new drug for treatment of pulmonary hypertension.
    Makowski CT; Rissmiller RW; Bullington WM
    Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and effectiveness of riociguat to treat chronic thromboembolic pulmonary hypertension.
    DeSouza SA; Preston IR
    Expert Rev Cardiovasc Ther; 2015 May; 13(5):467-76. PubMed ID: 25797801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Animal models related to congenital heart disease and clinical research in pulmonary hypertension.
    Loukanov T; Geiger R; Agrawal R
    Cardiology; 2010; 116(1):18-25. PubMed ID: 20424448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Riociguat (Adempas). Chronic thromboembolic pulmonary hypertension with markedly restricted physical activity.
    Prescrire Int; 2015 Nov; 24(165):265-6. PubMed ID: 26688897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.